Glucose lowering does not necessarily reduce cardiovascular risk in type 2 diabetes

Angeliki Bourazana, Grigoris Giamouzis, John Skoularigis, Filippos Triposkiadis, Andrew Xanthopoulos

Abstract

Diabetes mellitus (DM) is a health condition characterized by glucose dysregulation and affects millions of people worldwide. The presentation of heart failure in diabetic cardiomyopathy extends over a wide phenotypic spectrum, commencing from asymptomatic, subclinical structural abnormalities to severely symptomatic biventricular dysfunction with increased mortality risk. Similarly, the spectrum of systolic dysfunction in diabetic-induced heart failure is diverse. DM leads also to cardiac electrical remodeling reacting on various targets. Dipeptidyl peptidase-4 (DPP-4) inhibitors reduce glucagon and blood glucose levels by raising levels of the endogenous hormones glucagon-like-peptide 1 and glucose-dependent insulinotropic peptide and constitute a safe and effective glucose lowering treatment option in patients with type 2 DM. Despite DPP-4 inhibitors’ efficacy regarding glycemic control, their effect on cardiovascular outcomes (myocardial infarction, stroke, hospitalization for heart failure, hospitalization for unstable angina, hospitalization for coronary revascularization, and cardiovascular death) in diabetic patients has been neutral. The potential correlation between atrial flutter and DPP-4 inhibitors administration needs further investigation.

Key Words: Dipeptidyl peptidase-4 inhibitors; Diabetes mellitus; Outcomes; Meta-analysis; Heart failure; Atrial flutter
Core Tip: Dipeptidyl peptidase-4 inhibitors are a safe and effective glucose lowering treatment option in patients with type 2 diabetes mellitus. However, their effect on cardiovascular outcomes in diabetic patients has been neutral. The potential correlation between atrial flutter and dipeptidyl peptidase-4 inhibitors administration is an interesting finding, but since currently there is no sheer underlying pathophysiologic mechanism to justify it, more evidence is required.

Citation: Bourazana A, Giamouzis G, Skoularigis J, Tripkoskiadis F, Xanthopoulos A. Glucose lowering does not necessarily reduce cardiovascular risk in type 2 diabetes. World J Cardiol 2022; 14(4): 266-270

URL: https://www.wjgnet.com/1949-8462/full/v14/i4/266.htm

DOI: https://dx.doi.org/10.4330/wjc.v14.i4.266

TO THE EDITOR

Diabetes mellitus (DM) is a health condition characterized by glucose dysregulation and affects 237.9 million males and 222 million females worldwide[1]. It is an established risk factor of cardiovascular disease, atrial and ventricular arrhythmias, as well as sudden cardiac death[2,3]. Dipeptidyl peptidase-4 (DPP-4) inhibitors are a safe and effective glucose lowering treatment option in patients with type 2 DM (T2DM). Nevertheless, pooled recent data on the effect of DPP-4 inhibitors on cardiovascular outcomes and major cardiac arrhythmias are lacking.

We read with great interest the paper by Patoulias et al[4], who attempted to close the abovementioned knowledge gap by performing a meta-analysis of six randomized controlled trials (52520 patients) concerning the impact of dipeptidyl peptidase-4 (DPP-4) inhibitors on “hard” cardiovascular outcomes and major cardiac arrhythmias. The authors concluded that DPP-4 inhibitors, compared to placebo, had no effect on fatal or non-fatal myocardial infarction, fatal and non-fatal stroke, hospitalization for heart failure, hospitalization for unstable angina, hospitalization for coronary revascularization, and cardiovascular death and did not seem to confer any significant risk for major cardiac arrhythmias, with the exception of atrial flutter, which was associated with an increased risk equal to 52% (relative risk = 1.52, 95% confidence interval: 1.03-2.24, P = 0%).

We agree with the authors’ insight that the presence of DM per se increases the risk of adverse cardiovascular outcomes and arrhythmias and results in cellular destabilization of myocardial tissue altogether. For example, it has been demonstrated that diabetic patients present an increased propensity for developing heart failure[5]. Diabetic cardiomyopathy, defined as ventricular dysfunction in the absence of hypertension or coronary artery disease, has been attributed to the deregulated immune response in type-1 DM (T1DM) and to the background of obesity in the majority of T2DM patients. The amplified immune response of T1DM patients to myocardial injury, leads to the expansion of proinflammatory CD4+ T cells specific to myosin and the development of autoantibodies to MYH6 and other cardiac antigens. On the other hand, obesity that predominates over T2DM patients reduces the palliative actions of circulating natriuretic peptides on ventricular stress, pressure overload, and sympathetic activation. In the absence of natriuretic peptides’ favorable actions, left ventricle hypertrophy, fibrosis, and insulin desensitization in skeletal muscles are more frequently observed in obese patients[5]. The presentation of heart failure in diabetic cardiomyopathy extends over a wide phenotypic spectrum, commencing from asymptomatic, subclinical structural abnormalities, developing progressively to severely symptomatic biventricular dysfunction with advanced mortality risk. Similarly, the spectrum of systolic dysfunction in diabetic-induced heart failure is diverse, originating in the heterogeneous risk factors that diabetes comes along, such as hypertension, hyperlipidemia, cardiovascular disease, and chronic kidney disease[6].

Except for the morphological implications on ventricular myocardium that account for the wide spectrum of left ventricular dysfunction, DM leads to cardiac electrical remodeling reacting on various targets. Among the diabetes-induced electrical disturbances, reduced conduction velocity, prolonged repolarization, and increased QT dispersion have been recognized, all predisposing to ventricular arrhythmias[7,8]. T1DM and T2DM lead to action potential duration prolongation, which becomes prominent on electrocardiography with a QRS prolongation in some diabetic patients[9]. QT duration prolongation subsequently predisposes to early after depolarizations development and an enhanced risk of torsade de pointes[10]. The proposed mechanisms are diabetes-exerted alterations in the function of several proteins involved in ion handling. More specifically, DM modifies ion channels responsible for depolarization as well as repolarization and resting phase[11]. Therefore, DM affects essentially all phases of action potential and correlates strongly to ventricular arrhythmias emergence.

The culprit pathophysiologic mechanisms for the occurrence of atrial arrhythmias in DM substrate are not yet in depth elucidated. In atrial myocardium, DM favors the phenotypic switch of fibroblasts to myofibroblasts[12]. Might it is that diabetes induced atrial neuropathy as well as diabetes generated advanced myofibroblast differentiation promote atrial remodeling and lead to atrial cardiomyopathy.
Figure 1 Newer oral antidiabetic drugs, glucose levels, and cardiovascular risk. A: Dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter 2 inhibitors (SGLT-2i), and glucagon-like peptide-1 receptor agonists (GLP1-RA) are effective glucose lowering agents in patients with type 2 DM; B SGLT-2i and GLP1-RA have shown significant decreases in adverse cardiovascular events, whereas the effect of DPP-4 inhibitors on cardiovascular outcomes in diabetic patients has been neutral. DPP-4i: DPP-4 inhibitors; SGLT-2i: Sodium-glucose cotransporter 2 inhibitors; GLP1-RA: glucagon-like peptide-1 receptor agonists.

overall[13]. Nonetheless, on epidemiological basis, DM is a strong independent risk factor for atrial fibrillation (AF) and atrial flutter occurrence.

Several studies have demonstrated that antidiabetic drugs may have differing effects on the risk of new-onset AF[14]. Metformin has been associated with anti-atrial arrhythmic benefits[15]. A case control study revealed no association between sulfonylurea and incident AF, whereas the use of insulin was associated with increased risk of new-onset AF[16]. A recent meta-analysis showed that DPP-4 inhibitor treatment resulted in a non-significant decrease in the risk for AF, whereas both glucagon-like peptide-1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2-i) were associated with a significant decrease in the risk for AF, equal to 14% and 19%, respectively[17]. Liraglutide (a GLP1-RA) demonstrated favorable effects on electrophysiological changes regarding AF inducibility and conduction velocity decrease[18].

DPP-4 inhibitors reduce glucagon and blood glucose levels by raising levels of the endogenous hormones glucagon-like-peptide 1 and glucose-dependent insulinnotropic peptide, which are called incretins. Subsequently incretins inhibit glucagon release and increase insulin secretion. Despite DPP-4 inhibitors’ indisputable efficacy regarding glycemic control, their effect on cardiovascular outcomes in diabetic patients, as denoted in the aforementioned and previous studies, has been neutral[19,20]. Furthermore, the risk of hypoglycemia is admitted to be increased compared to SGLT2-i. SGLT2-i reduce hyperglycemia through inhibition of glucose reabsorption in the renal proximal tubules. Acting on glucose/Na co-transporter they promote natriuresis and display not solely hypoglycemic effects but also reduce major adverse cardiovascular events (cardiovascular and total mortality, fatal or nonfatal myocardial infarction, or stroke) and hospitalization for heart failure and improve outcome in chronic kidney disease in diabetic and non-diabetic patients[21]. GLP1-RA are oral hypoglycemic drugs that mimic the effects of the incretin hormone glucagon-like-peptide 1. GLP-RA stimulate insulin release, inhibit glucagon secretion, and slow gastric emptying. Liraglutide, albiglutide, and dualiglutide have all shown significant decreases in adverse cardiovascular events[22]. In line with this evidence, the European Society of Cardiology guidelines recommend the administration of SGLT-2i or GLP1-RA as a first option in the presence of high or remarkably high cardiovascular risk or of cardiovascular disease[23].

The potential correlation between atrial flutter and DPP-4 inhibitors administration is an interesting finding, but since there is no sheer underlying pathophysiologic mechanism to justify it, more evidence is required to establish this thesis as a widely accepted knowledge admissible in clinical practice. The authors speculated that the abovementioned correlation may stem from the inherent higher risk of atrial flutter that patients with DM carry[24]. However, it is also well known that DM per se is a risk factor of AF[24], which in the current meta-analysis was not associated with DPP-4 inhibitor use.

In conclusion, the authors should be congratulated on their attempt to provide state of the art data on the association between DPP-4 inhibitors and cardiovascular outcomes as well as major cardiac arrhythmias. The reported increased risk of atrial flutter in patients receiving DPP-4 inhibitors needs further investigation (Figure 1).
FOOTNOTES

Author contributions: Bourazana A and Xanthopoulos A wrote the letter; Giamouzis G, Skoularigis J, and Triposkiadis F revised the letter; All authors made substantial contributions to conception and design of the study, acquisition of data or analysis and interpretation of data, drafted the article or made critical revisions related to important intellectual content of the manuscript, and gave final approval of the version of the article to be published.

Conflict-of-interest statement: The authors declare no conflict of interest regarding the present work

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: Greece

ORCID number: Angeliki Bourazana 0000-0001-8297-4201; Grigorios Giamouzis 0000-0002-7406-5427; John Skoularigis 0000-0001-7159-2478; Filippos Triposkiadis 0000-0001-6433-4016; Andrew Xanthopoulos 0000-0002-9439-3946.

S-Editor: Ma YJ
L-Editor: Filipodia
P-Editor: Ma YJ

REFERENCES

1 Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Cheng S, Delling FN, Elkind MSV, Eveson KR, Ferguson JF, Gupta DK, Khan SS, Kissela BM, Knutson KL, Lee CD, Lewis TT, Liu J, Loop MS, Lutesy PL, Ma J, Mackey J, Martin SS, Matchar DB, Mussolino ME, Navaneethan SD, Perak AM, Roth GA, Samad Z, Satou GM, Schroeder EB, Shah SH, Shay CM, Stokes A, VanWagner LB, Wang NY, Tsao CW; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation 2021; 143: e254-e743 [PMID: 33501848 DOI: 10.1161/CIR.0000000000000950]

2 Bell DSH, Goncalves E. Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti-diabetic therapies. Diabetes Obes Metab 2019; 21: 210-217 [PMID: 30144274 DOI: 10.1111/dom.13512]

3 Lyne TH, Swane J, Pedersen-Bjaergaard U, Gislason G, Torp-Pedersen C, Banner J, Rigsbaard G, Winkel BG, Tfelt-Hansen J. Sudden cardiac death among persons with diabetes aged 1-49 years: a 10-year nationwide study of 14 294 deaths in Denmark. Eur Heart J 2020; 41: 2699-2706 [PMID: 31848583 DOI: 10.1093/eurheartj/ehz891]

4 Patoulias DI, Boulmpou A, Terpeklidis E, Katsimardou A, Siouxis F, Doumas M, Papadopoulos CE, Vassiliki V. Cardiovacular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials. World J Cardiol 2021; 13: 585-592 [PMID: 34754403 DOI: 10.1161/WJC.11.10.85]

5 Triposkiadis F, Xanthopoulos A, Bargiota A, Katsiki T, Katsiki N, Farmakis D, Skoularigis J, Starling RC, Iliodromitis E. Diabetes Mellitus and Heart Failure. J Clin Med 2021; 10 [PMID: 34441977 DOI: 10.3390/jcm10163682]

6 Triposkiadis F, Butler J, Abboud FM, Armstrong PW, Adamopoulos S, Atherton JJ, Backs J, Baurausch J, Burkoff D, Bonow RO, Chopra VK, de Boer RA, de Windt L, Hamdani N, Hasenfuss G, Heymans S, Huot JS, Konstam M, Lee RT, Linke WA, Lunde IG, Maack C, Mann DL, Mebazaa A, Mentz RJ, Nihoyannopoulos P, Papp Z, Parissis J, Pedrazzini T, Rosano G, Rouleau J, Seferovic PM, Shah AM, Starling RC, Tocchetti CG, Trochetti JN, Thum T, Zannad F, Brutsaert DL, Segers VF, De Keulenaer GW. The continuous heart failure spectrum: moving beyond an ejection fraction classification. Eur Heart J 2019; 40: 2155-2163 [PMID: 30957868 DOI: 10.1093/eurheartj/ehz158]

7 Ninkovic VM, Ninkovic SM, Miloradovic V, Stanosevic D, Babić M, Giga V, Dobric M, Tremlin N, Lalic N, Seferovic PM, Jakovljevic DG. Prevalence and risk factors for prolonged QT interval and QT dispersion in patients with type 2 diabetes. Acta Diabetol 2016; 53: 737-744 [PMID: 27107571 DOI: 10.1007/s00592-016-0864-y]

8 Gallego M, Zayas-Arrabal J, Alquiza A, Apellaniz B, Casio O. Electrical Features of the Diabetic Myocardium. Arrhythmic and Cardiovascular Safety Considerations in Diabetes. Front Pharmacol 2021; 12: 687256 [PMID: 34305590 DOI: 10.3389/fphar.2021.687256]

9 Singleton MJ, German C, Hari KJ, Saylor G, Herrington DM, Soliman EZ, Freedman BI, Bowden DW, Hlatky MA, Yehoba J. QRS duration is associated with all-cause mortality in type 2 diabetes. J Electrocardiol 2020; 58: 150-154 [PMID: 31895990 DOI: 10.1016/j.ejccard.2019.11.053]

10 Maruyama M, Lin SF, Xie Y, Chua SK, Joug J, Han S, Shinoara T, Shen MJ, Qu Z, Weiss JN, Chen PS. Genes of phase 3 early afterdepolarizations and triggered activity in acquired long-QT syndrome. Circ Arrhythm Electrophysiol 2021; 4: 103-111 [PMID: 32107882 DOI: 10.1161/CIRCEP.110.959064]

11 Yu P, Hu L, Xie J, Chen S, Huang L, Xu Z, Liu X, Zhou Q, Yuan P, Yan X, Jin J, Shen Y, Zhu W, Fu L, Chen Q, Yu J, Hu J, Cao Q, Wan R, Hong K. O-GlcNAcylation of cardiac Nav1.5 contributes to the development of arrhythmias in diabetic hearts. Int J Cardiol 2018; 260: 74-81 [PMID: 29530619 DOI: 10.1016/j.ijcard.2018.02.099]

12 Fowlkes V, Clark J, Fix C, Law BA, Morales MO, Qiao X, Ako-Asare K, Goldsmith JG, Carver W, Murray DB, Goldsmith EC. Type II diabetes promotes a myofibroblast phenotype in cardiac fibroblasts. Life Sci 2013; 92: 669-676 [PMID: 23333820 DOI: 10.1016/j.lfs.2013.01.003]
13. Wang A, Green JB, Halperin JL, Piccini JP Sr. Atrial Fibrillation and Diabetes Mellitus: JACC Review Topic of the Week. J Am Coll Cardiol 2019; 74: 1107-1115 [PMID: 31439220 DOI: 10.1016/j.jacc.2019.07.020]

14. Lee TW, Lee TI, Lin YK, Chen YC, Kao YH, Chen YJ. Effect of antidiabetic drugs on the risk of atrial fibrillation: mechanistic insights from clinical evidence and translational studies. Cell Mol Life Sci 2021; 78: 923-934 [PMID: 32965213 DOI: 10.1007/s00018-020-03648-y]

15. Nantsupawat T, Wongcharoen W, Chattipakorn SC, Chattipakorn N. Effects of metformin on atrial and ventricular arrhythmias: evidence from cell to patient. Cardiovasc Diabetol 2020; 19: 198 [PMID: 33234131 DOI: 10.1186/s12933-020-01176-4]

16. Liou YS, Yang FY, Chen HY, Jong GP. Antihyperglycemic drugs use and new-onset atrial fibrillation: A population-based nested case control study. PLoS One 2018; 13: e0197245 [PMID: 30161122 DOI: 10.1371/journal.pone.0197245]

17. Patoulias D, Toupourleka M, Papadopoulos C, Doumas M. Meta-analysis Evaluating the Risk of Atrial Fibrillation With Newer Antidiabetics Across the Cardiovascular and Renal Outcome Trials. Am J Cardiol 2021; 139: 139-141 [PMID: 33080212 DOI: 10.1016/j.amjcard.2020.10.030]

18. Nakamura H, Niwano S, Niwano H, Fukaya H, Murakami M, Kishihara J, Satoh A, Yoshizawa T, Ishizue N, Igarashi T, Fujiishi T, Ako J. Liraglutide suppresses atrial electrophysiological changes. Heart Vessels 2019; 34: 1389-1393 [PMID: 30762094 DOI: 10.1007/s00380-018-01327-4]

19. Sinha B, Ghosal S. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract 2019; 150: 8-16 [PMID: 30794833 DOI: 10.1016/j.diabres.2019.02.014]

20. Liu D, Jin B, Chen W, Yun P. Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis. BMC Pharmacol Toxicol 2019; 20: 15 [PMID: 30832701 DOI: 10.1186/s40360-019-0293-y]

21. Xiao L, Nie X, Cheng Y, Wang N. Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms. Cardiovasc Drugs Ther 2021; 35: 1253-1267 [PMID: 34273091 DOI: 10.1007/s10557-021-07216-9]

22. Sheahan KH, Wahlberg EA, Gilbert MP. An overview of GLP-1 agonists and recent cardiovascular outcomes trials. Postgrad Med J 2020; 96: 156-161 [PMID: 31801807 DOI: 10.1136/postgradmedj-2019-137186]

23. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson J, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roßi M, Sattar N, Seferović PM, Sousa-Uva M, Valensi P, Wheeler DC; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41: 255-323 [PMID: 31497854 DOI: 10.1093/eurheartj/ehz486]

24. Movahed MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol 2005; 105: 315-318 [PMID: 16274775 DOI: 10.1016/j.ijcard.2005.02.050]
